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Abstract 
The effects of various concentrations of ethanolic extracts of 
Vernonia amygdalina (VA) stem and root on some biochemical indices of 
liver function in streptozotocin-induced diabetic and non-diabetic rats treated 
with 200mg/kg b.w and 400mg/kg b.w was determined. LD50 value of 1000 
mg/kg was established. The oral administration of the extracts lasted for 28 
days. The rats were divided into five parallel groups of non-diabetic and 
diabetic rats, with six rats in each group. Group 1 received Dimethy 
sulfoxide(DMSO) and served as the negative control. Group 2 received 
200mg/kg b.w Vernonia amygdalina (stem), group 3 received 400mg/kg b.w 
Vernonia amygdalina (stem). Group 4 received 200mg/kg b.w Vernonia 
amygdalina (root). Group 5 was given 400mg/kg b.w Vernonia amygdalina 
(root). Both stem and root extracts (200 and 400) mg/kg b.w significantly 
improved body weight and reduced whole blood glucose levels to normal but 
not up to hypoglycaemic level in diabetic treated rats. Total protein and 
albumin in serum were increased in diabetic rats treated with stem (200 and 
400) mg/kg b.w respectively. The findings suggest that V. amygdalina 
ethanolic stem and root extracts is hepatoprotective in diabetic rats and may 
be of nutritional/ clinical  relevance amongst African populations for 
treatment of different ailments. 
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Introduction 
Streptozotocin (STZ) is a drug currently used to induce diabetes in 
animal models that resemble non obese type 2 diabetes mellitus (Nakamura 
et al., 2006).The chemistry of STZ describes a glucose moiety with highly 
reactive nitrosourea side chain. The glucose moiety direct its uptake by 
pancreatic beta cells with ease via binding to a membrane receptor recently 
identified to be glucose transporter 2 (GLUT2) (Thuselen et al., 1997). The 
nitrosourea side chain on the other hand is thought to initiate its cytotoxic 
action. The induction of diabetes with STZ increases the production of free 
radicals that damage the pancreatic DNA and thus affect insulin secretion 
(Oguni et al., 2003). This is achieved by depleting Nicotinamide adenine 
dinucleotide (NAD) which is a substrate of poly adenosine 
diphosphate(ADP) ribose synthetase, an enzyme which is used in DNA 
repair. 
In diabetes, lipid abnormalities, anaemia, alteration of liver and 
kidney functional indices have been implicated as major risk factors to the 
progression of microvascular and macro vascular complications (Mandade 
and Screenivas, 2011). 
The promotion of traditional African diets still remains a powerful 
weapon in the fight against diabetes.Different types of antidiabetic drugs 
such as biguanide, sulphonylurea, along with insulin has been employed for 
the treatment of diabetes. Still none of these drugs were able to cure the 
diseases without adverse reaction (Tolman and Chandramouli, 2003; Annes 
et al., 2007). 
Presently, there is a growing interest in herbal remedies due to the 
side effects associated with oral hypoglycaemic agent (Kim et al., 2006). 
Consequently, further scientific investigation is needed to validate the usage 
of these plant parts in accordance with the world health organization (http:// 
www.who.org)           
Vernonia amygdalina(VA) Del. popularly known as bitter leaf or 
etidot in Efik language, is a shrub of 2-5 m tall with petiolate green leaves of 
about 6 mm diameter. The leaves are characteristically bitter but the 
bitterness can be abated by boiling or by soaking in several changes of clean 
water (Burkill, 1985). The stem and root divested of the bark are used as 
chewing sticks in Nigeria. More importantly, the leaves are a very popular 
soup vegetable and have even been reported to be consumed by goats in 
some parts of Nigeria (Aregheore et al., 1998). 
All parts of the plant are pharmacologically useful. The roots and the 
leaves are used in ethnomedicine to treat fever, hiccups, kidney problems 
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and stomach discomfort among several other uses (Burkill, 1985; Hamowia 
and Saffaf, 1994).  Both aqueous and alcoholic extracts of the stem, bark, 
roots and leaves are reported to be extensively used as a purgative, 
antimalarial and in the treatment of eczema (Kupcham, 1971). The plant has 
acquired special relevance recently, having been proved in human medicine 
to possess potent antimalarial and antihelminthic properties (Abosi and 
Raseroka, 2003) as well as antitumorigenic properties (Izevbigie et al., 
2004).The plant has also an amazing antiparasitic efficacy in 
zoopharmacognosy as it is easily recognized and used for self medication by 
parasitized chimpanzees (Huffman, 2003).   
Despite these varied uses of the plant, there has been insufficient 
information on its toxicological potentials on the animal system of diabetic 
model.   
Although, the plant is used traditionally for the management of DM, 
there is still a need for scientific data to give credence to its usage in folklore 
medicine. A thorough search of the literature reveals that there is scanty 
information on the effect of this plant parts (stem and root) on blood glucose 
and pathophysiologic symptoms in diabetic model. The present study was 
therefore designed to investigate the effect of the ethanolic extract of 
Vernonia amygdalina (stem and root) on body weight and liver functional 
indices of STZ diabetic rat and normal rats. 
 
Materials And Methods 
Sample collection and preparation 
Vernonia amygdalina (VA) plants having been identified and 
authenticated by a Botanist (Dr Mike Eko) of the Department of Botany, 
University of Calabar, fresh roots were excavated and stem of the plant were 
harvested from Endocrine Farm, University of Calabar staff quarters, Cross 
River State, Nigeria. 
The roots and stems were thoroughly washed to remove debris and 
the earth remains. From these the barks were divested and thereafter chopped 
into bits and allowed to dry under shade. They were blended into fine 
powder using a Q-link electrical blender Model QBL-18L40. Three hundred 
and twenty grams (320) of the blended stem bark and Three hundred and 
seventy grams (370g) of the blended root barks were separately soaked in 
1200ml of ethyl alcohol (80% BDH) each, then they were vigorously 
agitated and allowed to stay in refrigerator for 48 hours at 4oC. The mixtures 
were first filtered with cheese cloth, then with WhatMan No 1 filter paper 
(24cm). The filtrates were then separately concentrated in vacuo using 
Rotary Evaporator (Model RE52A, China) to 10% of its original volume at 
37 oC - 40 oC. These were concentrated to complete dryness in water bath, 
yielding 35.6g (11.47%) of stem bark and 52g (14.40%) of root bark 
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extracts. The extracts were stored in a refrigerator from where aliquots were 
used for the administration. 
 
Animal handling 
Sixty albino rats (males and females) of Wistar strains weighing 120-
180g were used for this study. The rats were obtained from the animal house 
of the Department of Biochemistry, Faculty of Basic Medical Sciences, 
University of Calabar .They were acclimatized for one week then reweighed 
and housed in wooden cages with wire-mesh top and kept under controlled 
environmental conditions of temperature (28±20C), relative humidity 
(50±5%) and a 12 hour light/dark cycle. The animal facility was adequately 
ventilated and the animals maintained regularly on the commercial rat chow. 
Tap water and food were provided ad libitum throughout the experimental 
period 
 
Induction of experimental diabetes 
Diabetes was induced by intra-peritoneal injection of 65mg/kg b.w of 
streptozotocin (STZ), Batch No. U925 obtained from Sigma St. Louis, M.O. 
USA. Prior to diabetes induction, the animals were fasted for 12 hours. 
Confirmation of diabetes was done four days after induction (Fasting Blood 
Sugar), using One Touch Glucometer (Lifescan Inc 1995 Milpas, California, 
USA). Blood sample for the FBS determination was obtained from tail 
puncture of the rats, and animals with FBS ≥ 200mg/dl were considered 
diabetic and included in the study as diabetic animals.   
 
Determination of median lethal dose (Ld50) 
The median lethal dose (LD) of the extract was estimated using 
albino mice by intraperitoneal (i.p) route using the method of (Lorke, 1983) . 
 
Experimental Design 
Schedule for animal grouping and treatment is as shown in Table 2. 
The dosages of plant extracts used were according to the methods of 
Atangwho 2007a. Plant extracts were administered twice daily via orogastric 
intubation for 28 days (at 6.00 am and 6.00pm). At the end of 28 days, feed 
was withdrawn from the rats and they were fasted overnight, but with free 
access to water. They were then anaesthetized under chloroform vapours and 
sacrificed. Whole blood was collected via cardiac puncture using sterile 
syringes into plain tubes and allowed for about two hours to clot. The clotted 
blood was centrifuged at 3000rpm for 10mins for serum collection meant for 
biochemical assays.      
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Table 1: Experimental Design 
Group    Extracts /Doses Diabetic(n) Non Diabetic(n) 
(1)       Control (0.2ml 6 6 
DMSO)   
 
STEM EXTRACT 
  
(2)       200mg/kg b.w 6 6 
(3)       400kg/kg b.w 6 6 
   
ROOT EXTRACT   
(4)      200mg/kg b.w 6 6 
(5)      400kg/kg b.w 6 6 
   
DMSO = Dimethylsulfoxide         n = number of rats per group      
b.w = body weight  
 
Glucose Estimation 
Randox-assay kit (CHOD-PAP) method based on Barham and 
Trinder (1972) was used. The principle involves the enzymatic oxidation of 
glucose in sample by the enzyme Glucose oxidase which generates hydrogen 
peroxide and gluconic acid. The concentration of H2O2 released is 
proportional to the initial amount of glucose in the sample and it reacts under 
catalysis of peroxidase, with phenol and 4-aminophenazone to form a red 
violet quinoneimine dye whose colour intensity reflects the concentration of 
glucose in the sample. 
 
Alanine aminotransaminase (ALT) 
Estimation of alanine aminotransaminase (ALT) activity is done 
using randox kit based on Reitman and Frankel (1957). 
 
α-oxoglutarate + L-alanine     ALT                 L-glutarate + pyruvate 
 
Pyruvate whose concentration depends on the amount of L-alanine 
transaminated and the activity of ALT is measured by monitoring the 
concentration of pyruvate hydrazone formed with (2, 4-dinitrophenyl) 
hydrazine at 546nM. 
 
Aspartate aminotransaminase (AST) 
Principle:Estimation of aspartate aminotransaminase (AST) activity 
is done using randox kit based on Reitman and Frankel (1957). 
  
α-oxoglutarate    +   L- aspartate        AST          L-glutamate + oxaloacetate 
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oxaloacetate, with concentration in proportion to aspartate consumed by 
enzyme and hence  its activity is measured by monitoring the concentration 
of oxaloacetate hydrazone formed with (2, 4- dinitrophenyl) hydrazine.    
 
Alkaline phosphatase (ALP) 
Determination of Serum Alkaline Phosphatase activity is done using 
the method of Baker and Silverton (1985). Absorbances of the samples were 
read on a spectrophotometer at 400nm against water blank. 
 
Total Protein 
Total protein is done using Randox assay kit (Biuret Method) as 
described by Tietz (1976). 
Principle: The method is based on the knowledge that cupric ions in 
an alkaline medium, interact with protein peptide bonds resulting in the 
formation of a purple-coloured copper- protein complex which is read 
colorimetrically at 540nm.     
 
Albumin 
Determination of albumin using Randox assay Kit (Bromocresol 
Green) based on Grant (1987).Albumin measurement is based on its 
quantitative binding to the indicator, bromocresol green, BCG (3,3’,5,5’,- 
tetra bromo- m cresol sulfonpthalein). The albumin-BCG- complex formed 
absorbed at 578nM and its colour intensity is directly proportional to the 
concentration of albumin in the sample. 
 
Total Bilirubin 
Total  bilirubins was determined according to the method of Malloy 
and Evelyn (1937) as modified by Tietz (1976).Total bilirubin was 
determined in the presence of caffeine benzoate which releases albumin-
bound bilirubin. Bilirubin then reacts with diazotized sulphanilic acid to 
form pink-coloured azobilirubin which in the presence of alkaline tartrate is 
converted to green colour. 
 
Statistical Analysis 
Glucose and electrolyte measurements are presented as mean ± SE. 
One way Analysis of Variance (ANOVA) and the LSD post hoc test were 
used to analyse the data (p<0.05). 
 
Result 
Acute toxicity test  
The mean effective dose or medial lethal dose of the extract was 
investigated using 36 mice on test doses of 100-2000mg/kg body weight. At 
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the end of twenty four hours in each case, no deaths were recorded within 
this dose range and no overt manifestation of toxicity was observed up to the 
dose level of 2000mg/kg body weight. The whole experiment was repeated 
by gavaging the dose levels again i.e. 3000mg/kg, 4000mg/kg and 
5000mg/kg body weight respectively to another set of mice for a period of 
24hrs. As was the case in the first test, no deaths were yet recorded nor was 
overt manifestation of toxicity observed. Therefore, the lower dose level of 
200mg/kg and 400mg/kg body weight were chosen as the tolerable doses of 
the extract. 
Table 2( a and b)  and 3 (and b) show the effects of administration of 
V.amygdalina stem bark and root bark extract for 28 days on body weight 
and fasting blood glucose in normal and STZ-induced diabetic rats. Body 
weight and fasting blood glucose significantly increased in diabetic rats 
when compared to the non diabetic control. Both stem and root extract (200 
and 400) mg/kg b.w significantly improved body weight and brought down 
whole blood glucose towards normal but not up to hypoglycaemic level. 
Weight variation in non diabetic rats of both control and treated 
groups showed a similar trend weight appreciation at the end of 28th day. 
However V.amygdalina root extract treatment 200mg/kg and 400mg/kg b.w 
showed smaller increase in weight (reduced increase) compared to other 
treatment groups and the control. Administration of V.amygdalina stem Bark 
(200mg/kg and 400mg/kg) to non diabetic rats increases the fasting blood 
glucose and they compared well with their respective non diabetic controls. 
Glucose concentration in blood serum of diabetic control animal was 
significantly increased by about 6.4 fold compared to non diabetic control. 
Treatment with V.amygdalina stem extracts significantly reduces (p<0.05) 
serum glucose in diabetic treated rats relative to  the diabetic control, as non 
diabetic rats treated with root extracts200mg/kg had serum (8.69±3.24) 
glucose level reduced significantly (p<0.05) compared to the non diabetic 
value (36.69±4.28). Serum Amino transferase activities (AST and ALT) 
were raised by 1.6 and 2.3 fold respectively in the diabetic control relative to 
non diabetic control. 
Treatment with V.amygdalina stem 200mgkg and 400mg/kg b.w 
caused significant reduction p<0.05 in AST and ALT respectively in diabetic 
treatment groups relative to diabetic control. No significant change was 
observed in V.amygdalina root treated diabetic groups even though there was 
a reduction in serum values of AST and ALT. Administration of 
V.amygdalina stem (400mg/kg) alone to non diabetic rats caused significant 
increase (p<0.05) In ALT activity unlike V.amygdalina stem 200mg/kg, 
V.amygdalina root 200mg/kg and 400mg/kg b.w caused no significant 
increase in ALT activity. Alkaline phosphatase (ALP) activity showed no 
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significant change in both treated diabetic and non diabetic rats administered 
with V.amygdalina root 400mg/kg b.w extract relative to control. 
The induction of diabetes in rats significantly (p<0.05) reduced the 
levels of total protein and albumin when compared to the non diabetic 
control. The result showed no significant increase in total bilirubin between 
the various treatment groups. Treatment of diabetic rats with V.amygdalina 
stem extracts at doses of 200 (82.01±0.02) and root extract at doses of 200 
(48.01±1.78) increased remarkably (p<0.05) for total protein and albumin 
respectively. Levels of serum total protein and albumin significantly 
increased (p<0.05) following treatment with V.amygdalina stem 200mg/kg 
b.w extract in non diabetic rats compared to the non diabetic control. 
Table 2a: Effect on treatment on body weight and Fasting Blood Glucose in diabetic rats. 
 Body weight Fasting blood glucose 
Group Treatment 0 day 28th day 0 day 28th Day 
Normal control 150.05±0.01 170.02±0.04 56.52±2.86 78.68±3.92 
Diabetic control 168.04±0.17 137.01±1.02* 226.25±18.90 246.55±3.34a 
Stem(200mg/kg)D 169.02±0.09 176.06±0.05*a 228.49±2.78 122.51±6.05 a 
Stem(400mg/kg)D 172.02±0.65 178.06±0.07* 240.00±8.57 95.52±14.42 a 
Root(200mg/kg)D 165.03±0.09 172.06±0.69 253.67±3.20 119.39±0.94 a 
Root(400mg/kg)D 162.21±1.45 164.01±2.03* 248.69±2.89 130.058.19 a 
Values are expressed as Mean ± SD, n=6, *P<0.05 vs NC; a = P<0.05 vs DC 
D = Diabetic 
 
Table 2b: Effect on treatment on body weight and Fasting Blood Glucose in non diabetic 
rats 
 Body weight Fasting blood glucose 
Group Treatment 0 day 28th day 0 day 28th Day 
Normal control 150.05±0.01 170.02±0.04 56.52±2.86 78.68±3.92 
Stem(200mg/kg)ND 159.25±5.60 182.20±4.50a 54.60±4.97 76.20±.80* 
Stem(400mg/kg)ND 165.90±3.20 186.30±6.90a 64.00±0.09 77.00±2.96* 
Root(200mg/kg)ND 200.85±10.90 222.48±5.85 69.81±9.61 68.01±0.90 
Root(400mg/kg)ND 185.20±6.22 200.60±3.18 58.90±6.80 35.60±5.95 
Values are expressed as Mean ± SD, n=6, *P<0.05 vs NC; a = P<0.05 vs DC 
NC =normal control, DC =Diabetic control ND=Non diabetic 
 
Table 3a: Effect of treatments on serum glucose and liver function indices in diabetic rats. 
Group 
Treatment 
Glucose 
Mg/dl 
ALP 
(U/L) 
AST 
(U/L) 
ALT 
(U/L) 
T.Protei
n 
(Mg/dl) 
Albumi
n 
(Mg/dl) 
T.BIliru
bin 
(Mg/dl) 
Normal 
control 
36.69±4.
28 
80.14±6.
17 
75.07±6.
75 
26.13±
1.71 
79.90±0
.35 
47.9±6.
52 
7.80±0.
90 
Diabetic 
control 
233.46±2
3.40 
142.14±
0.55 
121.84±
6.92a 
61.21±
7.47a 
63.19±0
.35a 
29.44±
1.13a 
43.70±1
0.80 
Stem(200m
g/kg)D 
107.59±7
.25a* 
98.64±7.
51 
89.16±8.
70a 
31.43±
2.93a 
82.01±0
.02 
48.01±
1.78 
44.30±5
.80 
Stem(400m
g/kg)D 
98.04±6.
86a* 
89.74±7.
93 
85.41±4.
60 
28.82±
1.52a 
78.52±5
.88a 
59.05±
2.50 
40.07±0
.80 
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Root(200m
g/kg)D 
126.21±1
9.26 
130.56±
21.90 
105.00±
9.70 
40.26±
19.8 
64.21±1
0.19 
38.20±
9.76 
38.80±5
.29 
Root(400m
g/kg)D 
116.41±2
1.80 
133.68±
15.90 
115.40±
2.20 
38.72±
16.7 
72.80±1
6.5 
46.08±
1.08 
43.08±0
.90 
Values are expressed as Mean ± SD, n=6, *P<0.05 vs NC; a = P<0.05 vs DC 
NC =normal control, DC =Diabetic control D = Diabetic 
 
Table 3b: Effect of treatments on serum glucose and liver function indices in non- diabetic 
rats. 
Group 
Treatment 
Glucose 
Mg/dl 
ALP 
(U/L) 
AST 
(U/L) 
ALT 
(U/L) 
T.Protei
n 
(Mg/dl) 
Albumi
n 
(Mg/dl) 
T.BIliru
bin 
(Mg/dl) 
Normal 
control 
36.69±
4.28 
80.14±6.
17 
75.07±
6.75 
26.13±1.
71 
79.90±0.
35 
47.90±
6.52 
7.80±0.
80 
Stem(200mg/
kg)ND 
28.70±
9.36 
76.48±4.
82 
74.89±
1.13 
24.33±2.
39 
82.40±5.
40* 
61.40±
0.04 
8.90±9.
70 
Stem(400mg/
kg)ND 
19.28±
4.45 
78.29±1
0.90 
71.98±
0.14 
25.28±9.
32* 
85.30±0.
02 
57.3±0.
08 
10.80±
0.50 
Root(200mg/
kg)ND 
8.69±3.
24* 
69.29±7.
60 
72.69±
8.80 
22.82±4.
81 
92.10±0.
00 
58.70±
0.02 
7.50±6.
40 
Root(400mg/
kg)ND 
12.38±
4.28 
72.23±1.
45* 
78.62±
4.90 
18.90±2.
42 
88.20±0.
92 
55.60±
1.90 
7.78±0.
54 
Values are expressed as Mean ± SD, n=6, *P<0.05 vs NC; a = P<0.05 vs DC 
ND=non diabetic   NC =normal control, DC =Diabetic control 
 
Discussion 
In acute toxicity test, a total of 25 mice were used according to the 
method of Lorke (1983) for the determination of the dose extract that will 
produce the effect in 50% of the animal treated. At the end of the twenty four 
hours in each case, none of the doses gave a positive result and no ovate 
manifestation of toxicity was observed from 100mg/kg body weight up to a 
dose level of 5000mg/kg body weight. 
Streptozotocin-induced diabetes is characterized by a severe loss in 
body weight (Al-Shamaorry et al., 1994), which might be the result of 
protein wasting due to unavailability of carbohydrate as an energy source 
(Chen and Ianuzzo, 1982). Tissue waisting is a characteristic of poor 
glycemic control in diabetes and this usually foster protein and fat 
mobilization (Cotran et al., 1999). Atangwho et al., 2007a and Okokon et al., 
2011 reported significant weight reduction in untreated diabetic animals. 
This was also observed in the present study with untreated diabetes. The 
sustained but gradual reduction in weight of untreated diabetic rats over 28 
days clearly indicated the deterioration in glucose control mechanism. This 
observation is a direct inverse of changes in blood glucose which rather 
increases over the period, hence establishing inverse relationship between 
blood glucose and weight changes in untreated diabetes. Treatment of 
diabetic rats with ethanolic root stem extract of  V.amygdalina improved the 
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weight gain compared to untreated diabetic rats (Table 3a and 3b).The 
gradual appreciation in weight upon treatment indicates that the treatment 
would have allowed the tissues access to glucose, both to supply energy and 
build tissue material needed for growth (Atangwho et al.,2007a). 
The cardinal body fluid parameter in diagnosis and progress 
monitoring, as a response to the treatment of diabetes mellitus has lesser 
blood glucose concentration (Loeb,1991).Fasting blood glucose at the end of 
28 days treatment measured in the blood and serum of untreated diabetic rats 
was significantly higher (P<0.05) than non diabetic control by 3.1 and 6.4 
folds respectively. Treatment caused significant decrease in serum glucose 
only with V.amygdalina stem (200 and 400) mg/kg b.w but a non significant 
reduction with V.amygdalina root extract (200mg/kg), which caused a 
significant reduction in treated non diabetic rats. The observed reduction in 
blood serum glucose of diabetics, is in accordance with Ebong et al., (2008) 
earlier report on the V.amygdalina leaves. Some plants' extracts are reported 
to exert hypoglycaemic action by potentiating the insulin effect, either by 
increasing the pancreatic secretion of insulin from the cells of islets of 
langerhans or its release from bound insulin (Pari and Amarnah, 2004), while 
others act through extra pancreatic mechanisms by inhibition of hepatic 
glucose production (Edduoks et al., 2003) or corrections of insulin resistance 
(Hu et al., 2003). This stem extract may have acted through one of these 
mechanisms. The reduction in serum glucose of diabetics treated with stem 
extract relative to diabetic control probably may imply insulin mimetic 
action. 
Enzymes appear frequently in blood as a result of cellular injury.The 
most widely used enzymes to assess hepatocellular injury are the 
aminotransferase (ALT and AST) whereas alkaline phosphatises are useful 
in diagnosis of hepatobilliary or cholestatic obstruction (Johnson and Fody, 
1992).in this study, the damage caused by STZ was substantiated by the 
elevated level of AST, ALT and ALP in diabetic control rat. The increase 
might be due to leakages from the cytosol or changes in the permeability of 
the liver membrane. However treatment for 28days with stem and root 
extracts of V.amygdalina reduced the activity of this enzymes in a dose 
related manner compared with the diabetic control thus improving renal and 
hepatic functions. This observation concurred with report of Atangwho et al., 
2007c who reported the hepatoprotective effect of leaves extract of 
V.amygdalina in diabetic rat, its terpenoid extracts against carbon 
tetrachloride induced hepatotoxicity has equally been reported (Babalola et 
al., 2001). 
The data obtained from this study show significantly (p<0.05) 
decreased levels of total protein, albumin and increased total bilirubin in 
diabetic control group and this is consistent with the investigation  when 
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compared to non diabetic control group (Tumevo et al., 2007) and Bakris, 
2007). The administration of stem extract alone caused significant increased 
in total protein and albumin as compared with normal group which indicates 
stabilization of plasma membrane and protection of liver cell membrane. 
  
Conclusion 
The results of this study show that ethanolic stem and root extract of 
Vernonia amygdalina possess antidiabetic properties and liver function 
maintenance. This confirmation justifies its use in ethno medicine for the 
treatment of diabetes. 
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